MDXG

Mimedx Group Stock Analysis

AI Rating

Good
  • Quality9/10
  • Growth↓ 4/10
  • Value↑ 7/10
Mimedx Group sales and earnings growth
MDXG Growth
Neutral
  • Revenue Y/Y↑ 19.99%
  • EPS Y/Y↑ 13.79%
  • FCF Y/Y↑ 13.11%
Mimedx Group gross and profit margin trends
MDXG Profitability
Great
  • Gross margin ↑ 82.60%
  • EPS margin↑ 11.60%
  • ROIC 5Y↑ 36.05%
Mimedx Group net debt vs free cash flow
MDXG Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↑ 21.6

Mimedx Group stock is less volatile than the overall market, so it's low risk. We give it a Great risk rating.

More Biotechnology stocks ↗